financetom
Business
financetom
/
Business
/
SPX Technologies Plans $500 Million Common Stock Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SPX Technologies Plans $500 Million Common Stock Offering
Aug 12, 2025 12:45 AM

03:16 AM EDT, 08/12/2025 (MT Newswires) -- SPX Technologies ( SPXC ) said late Monday it plans to offer $500 million worth of common shares in an underwritten public offering.

The underwriters are expected to have a 30-day option to buy up to $75 million of additional shares.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Kenvue Maintains Quarterly Dividend at $0.205 per Share; Payable on Nov. 27 to Shareholders of Record on Nov. 13
--Kenvue Maintains Quarterly Dividend at $0.205 per Share; Payable on Nov. 27 to Shareholders of Record on Nov. 13
Oct 17, 2024
07:29 AM EDT, 10/17/2024 (MT Newswires) -- Price: 21.76, Change: +0.03, Percent Change: +0.14 ...
Infosys' Fiscal Q2 Earnings, Revenue Rise
Infosys' Fiscal Q2 Earnings, Revenue Rise
Oct 17, 2024
07:01 AM EDT, 10/17/2024 (MT Newswires) -- Infosys ( INFY ) reported fiscal Q2 earnings Thursday of $0.19 per diluted share, up from $0.18 a year earlier. Analysts polled by Capital IQ expected $0.19. Revenue for the quarter ended Sept. 30 was $4.89 billion, up from $4.72 billion a year earlier. Analysts surveyed by Capital IQ expected $4.86 billion. The...
Iridium Communications Swings to Q3 Net Income, Revenue Rises
Iridium Communications Swings to Q3 Net Income, Revenue Rises
Oct 17, 2024
07:26 AM EDT, 10/17/2024 (MT Newswires) -- Iridium Communications ( IRDM ) reported Q3 net income Thursday of $0.21 per diluted share, swinging from a net loss of $0.01 a year earlier. Analysts polled by Capital IQ expected earnings of $0.19. Revenue for the quarter ended Sept. 30 was $212.8 million, up from $197.6 million a year earlier. Analysts surveyed...
Travere Therapeutics Receives Swiss Regulator's Temporary Marketing Approval for Kidney Disease Treatment
Travere Therapeutics Receives Swiss Regulator's Temporary Marketing Approval for Kidney Disease Treatment
Oct 17, 2024
07:26 AM EDT, 10/17/2024 (MT Newswires) -- Travere Therapeutics ( TVTX ) said Thursday that Swissmedic offered temporary marketing approval for Filspari to treat adults with primary IgA nephropathy with a urine protein excretion of at least 1 gram per day. The Swiss regulator's approval is supported by results from a phase 3 study and follows the US Food and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved